Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 1990Clinical Infectious Diseases

Overview of the Preclinical Development of an Antiretroviral Drug, 2′,3′-Dideoxyinosine

View Full Paper
Ask AI
Bookmark
Share

Authors

JMJohn J. McGowanEdinburgh Napier UniversityJTJoseph E. TomaszewskiAmerican Society for Bone and Mineral ResearchJCJames C. CradockNational Institutes of Health

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

McGowan et al. (1990) studied this question.

synapsesocial.com/papers/6ab5c4d453af88fca83cf341https://doi.org/10.1093/clinids/12.supplement_5.s513
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.1986 · 1,042 citations
  2. 2Effect of the structure of the glycon on the acid-catalyzed hydrolysis of adenine nucleosides1981 · 100 citations
  3. 3Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides.1988 · 232 citations